Skip to main content

TRAF-STOP therapy to reduCe inflammation in athERosclerosis.

Project description

A novel oral drug for atherosclerosis is moving toward clinical application

Atherosclerosis was long considered a lipid storage disease as it is characterised by an accumulation of cholesterol and other lipids within the artery wall. It is now also recognised as a chronic inflammatory disease involving the immune system. Inhibitors of a key mediator of cell-cell communication in immunity can prevent initiation of plaque formation and retard its progression. However, in the long-term immunity is suppressed as well. TRACER scientists discovered a potentially more specific target downstream of that system that reduces existing atherosclerosis without suppressing immunity. With EU support, they are now paving the way to bring an oral drug to patients. Better success in treating atherosclerosis should help in significantly lowering the incidence of associated cardiovascular diseases.

Host institution

ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM
Net EU contribution
€ 150 000,00
Address
Meibergdreef 15
1105AZ Amsterdam
Netherlands

See on map

Region
West-Nederland Noord-Holland Groot-Amsterdam
Activity type
Higher or Secondary Education Establishments
Other funding
No data

Beneficiaries (1)

ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM
Netherlands
Net EU contribution
€ 150 000,00
Address
Meibergdreef 15
1105AZ Amsterdam

See on map

Region
West-Nederland Noord-Holland Groot-Amsterdam
Activity type
Higher or Secondary Education Establishments
Other funding
No data